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ABSTRACT  
Berberine is a well-known plant alkaloid with a long history of medicinal use in Ayurvedic, Chinese, and South Asian 
traditional medicine. It can be found in the roots, rhizomes, and the bark of a number of plants. Plant extracts and decoctions 
involving berberine have demonstrated significant antimicrobial activity against a variety of organisms, intestinal parasite 
infections, and ocular trachoma infections. Positive action has been recorded against hypertension, tumors, inflammation, and 
HIV. It also has anti-protozoal, chloretic, cholagogue, cardiotonic, anti-cholinergic, anti-arrhythmic effects, and anti-platelet 
aggregation. This original review of berberine outlines its physiological effects.  
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Introduction 
§Berberine is a well-known plant alkaloid with a long 
history of use in Ayurvedic, Chinese, and South Asian 
traditional medicine. It is a component of plants such as 
Hydrastis canadensis (goldenseal), Coptis chinensis 
(Coptis or goldenthread), Berberis aquifolium (Oregon 
grape), Berberis vulgaris (barberry), Berberis aristata 
(tree turmeric) (Berberis species), and Arcangelisia flava. 
It is found in roots, rhizomes, and bark of these plants. 
Berberine has several uses. For example, plant extracts 
and decoctions have significant antimicrobial activity 
against a variety of organisms such as bacteria, viruses, 
fungi, protozoans, helminthes, and chlamydia. Currently, 
the predominant clinical uses of berberine involve cases 
of bacterial diarrhea, intestinal parasite infections, and 
ocular trachoma infection.1 It exhibits multiple 
pharmacological activities qualities such as being active 
against hypertension, tumors, bacteria, inflammation, and 
HIV. It also has anti-protozoal, chloretic, cholagogue, 
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cardiotonic, anti-cholinergic, anti-arrhythmic effects, and 
anti-platelet aggregation. Some actions of berberine have 
been extensively studied and are addressed in the 
following sections. 
 
Anti-diarrheal action 
Berberine has been used for centuries in different 
parts of the world and is also used in the modern 
treatment of diarrhea. Its actions in this regard are 
manifested by its anti-cholinergic.2 α2-adrenoreceptor 
agonistic3, anti-secretory4 and/or antimicrobial effects.5,6 
In in vivo study by Swabb et al (1981), berberine 
reduced the intestinal transit time of the secretion of 
water and electrolytes induced by cholera toxin.7 It has 
also been shown to directly inhibit some V. cholera and 
E. coli enterotoxin8, reduce smooth muscle contraction 
and intestinal motility6, and delay intestinal transit time in 
humans. In the case of E. coli, in vitro research indicated 
that berberine sulfate is able to inhibit bacterial 
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adherence to mucosal or epithelial surfaces, the first step 
in the infective process. This may be a result of its 
inhibitory effect on fimbrial structure formation on the 
surface of the treated bacteria.9 In animal study, 
berberine significantly inhibited both the diarrhea induced 
by castor oil and that induced by BaCl2 at doses higher 
than 25 mg/kg given orally, but it did not inhibit diarrhea 
induced by pilocarpine or serotonin even at 250 mg/kg. 
Berberine inhibited acetylcholine (Ach) - or Ba2+-induced 
contraction of the ileum and colon at the concentration of 
about 10-5 g/mL.10 
 
Anti-malarial action 
Berberine has been used for the treatment of malaria. 
In Vietnam, it was collected from 14 medicinal plants and 
used in traditional treatment of the disease. Twenty-four 
extracts from these plants were found to have anti-
plasmodial effects inhibiting the growth of the 
chloroquine-resistant P. falciparum strain FCR-3 with 
EC50 values of less than 10 µg/mL. The methanol extract 
of Coscinium fenestratum was found to have the 
strongest anti-plasmodial effect with EC50 value of 0.5 
µg/mL. Activity-guided fractionation led to the 
identification of berberine as the major activity 
component.11 Sriwilaijareon et al (2002) examined 
telomerase activity in synchronized P. falciparum during 
its erythrocytic cycle using the telomerase repeat 
amplification protocol (TRAP).12 They reported that 
berberine extract inhibited telomerase activity in a dose-
dependent manner over a range of 30-300 µM. It 
indicated that P. falciparum telomerase might be a 
potential target for future malaria chemotherapy. 
 
Anti-tumor action 
Berberine possesses anti-tumor properties as 
evidenced by the inhibition of cyclooxygenase-2 (COX-2) 
transcription and N-acetyltransferase (NAT) activity in 
colon and bladder cancer cell lines.13,14 Its action is 
transient but markedly inhibits the growth of mouse 
sarcoma cells in culture. Wang et al (2002) reported the 
anti-neoplastic action of berberine in rats.15 The alkaloid 
inhibited and decreased aryamine NAT activity, levels of 
mRNA NAT1, and 2-aminofluorence-DNA (AF-DNA) 
adduct formation in human brain tumor cell lines 
(G95/VGH and GBM 8401) in a dose-dependent manner. 
Results showed that berberine apparently decreased the 
values of Km and Vmax of NAT of both cells. The results 
also indicated that berberine is a non-competitive 
inhibitor. In human leukemia cells, the NAT activity and 
AF-DNA adduct formation were inhibited by berberine in 
a dose-dependent manner, the higher the concentration 
of berberine, the higher the inhibition of NAT activity and 
AF-DNA adduct. It was also shown that berberine inhibits 
the viability and NAT activity in human tumor cells line 
and human bladder tumor cells in dose-dependent 
manner, that is the higher the concentration of berberine, 
the higher the inhibition of NAT activity. The apparent 
values of Km and Vmax of NAT from colon tumor cells 
were also inhibited by berberine in cytosols and in intact 
cells. Studies illustrated that berberine did not affect 
human colon tumor cell and NAT activity in human 
bladder tumor cell.13,14,16  Moreover, it has been shown to 
have an anti-cachectic effect on esophageal cancer. Its 
effect is associated with the ability to down-regulate 
tumor IL-6 production.17 Lin et al (2008) studied the 
viability of rat C6 and human U-87 glioma cells after 
treatment with As2O3 or berberine.18 They found that both 
significantly decreased the activation of PCK α and ε 
and led to actin cytoskeleton rearrangements. The levels 
of two downstream transcription factors, myc and jun, 
and MTI-MMP and MMP-2 were also significantly 
reduced. These results indicated that upon co-treatment 
of glioma cells with As2O3 and berberine, cancer cell 
metastasis can be significantly inhibited, most likely by 
blocking the PKC-mediated signaling pathway involved in 
cancer cell migration. This has potential in the 
development of new chemotherapeutic approaches in the 
treatment of malignant glioma and cancer in general. 
In in vitro study, the continuous exposure of HepG2 
cells to various concentrations (1-50 µM) of berberine 
resulted in growth inhibition in a dose-dependent 
manner.19 The viability of berberine-treated HepG2 cells 
was greater than 90% in all treated groups. Flow 
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cytometric analysis of berberine-treated HepG2 cells 
showed that the S phase fraction was significantly 
reduced. The levels of glucocorticoid receptors (GR) in 
berberine-treated HepG2 cells were higher than those in 
vehicle (DMSO)-treated cells. In addition, berberine 
inhibited the secretion of alpha-fetoprotein by HepG2 
cells suggesting that berberine-induced cell growth arrest 
was partially reversible in HepG2 cells. Cameron et al 
(2008) investigated the effect of berberine on PCSK9 
expression in HepG2 cells.20 They found that berberine 
decreases PCSK9 mRNA and protein levels in a time- 
and dose-dependent manner. This was not due to 
increase degradation of PCSK9 mRNA but most likely 
due to a decreased transcription of the PCSK9 gene. 
This suggested that berberine may be a useful 
supplement to statin treatment in lipid lowering drugs, 
due to its effect on PCSK9 mRNA and protein levels.  
 
Cardiovascular action 
Both clinical trials and animal research have indicated 
that the administration of berberine prevents ischemia-
induced ventricular tachyarrhythmia. It stimulates cardiac 
contractility and lowers peripheral vascular resistance 
and blood pressure.21,22 An animal study by Wang et al 
(1994) indicated that berberine may suppress the 
delayed after-depolarization in the ventricular muscle.23 
Some cardiovascular effects of berberine are attributed 
to the blockage of K+ channels (delayed rectifier and K+ 
(ATP)) and the stimulation of Na+-Ca2+ exchange. 
Berberine has been shown to prolong the duration of 
ventricular action potential.24 In addition to the several 
effects on other parameters of cardiac performance, 
berberine may have vasodilating and antihypertensive 
effects attributable to the potential of Ach.21  
 
Anti-inflammatory and antihepatotoxic actions  
Berberine is an effective anti-inflammatory agent. In 
vitro studies utilizing human cell lines demonstrated that 
it inhibits activator protein 1 (AP-1), a key transcription 
factor in inflammation and carcinogenesis.14 By using 
human peripheral lymphocytes, berberine exerts a 
significant inhibitory effect on lymphocyte transformation. 
It was suggested that its anti-inflammatory action may be 
due to the inhibition of DNA synthesis in activated 
lymphocytes.25 In a study on platelet activation in 
response to tissue injury, berberine was shown to have a 
direct effect on several aspects of the inflammatory 
process. It exhibits a dose-dependent inhibition of 
arachidonic acid release from the cell membrane 
phospholipids, reduces thromboxan A2 from platelet26, 
and decreases thrombus formation.27 Recently, Janbaz 
and Gilani (2000) demonstrated the preventive effects of 
berberine (oral dose of 4 mg/kg) against acetaminophen 
and carbon tetrachloride (CCl4) -induced hepatotoxicity 
by which it inhibited the activities of microsomal drug 
metabolizing enzymes, CYPs.28 Surprisingly, it was 
believed that berberine has a selective curative effect 
related to acetaminophen but not CCl4 due to its 
antioxidative role. This was further supported by reports 
that the acetaminophen toxicity is chiefly due to the 
oxidative stress and is effectively improved by 
antioxidants.29 Berberine is also an effective antioxidant. 
Castro et al (1974) and Nelson et al (1980) reported that 
the inhibitors of cytochrome P450s (CYPs) can impair 
the bio-activation of CCl4 into its respective reactive 
species and provide protection against the prevailing 
hepatocellular damage.30,31 
Hwang et al (2002) studied the mechanism of the 
inhibitory effects of berberine on the tert-butyl 
hydroperoxide (t-BHP)-induced cytotoxicity and lipid 
peroxidation in rat’s livers. They found that berberine 
expressed an antioxidative property by its capacity for 
quenching the free radicals of 1,1-diphenyl-2-
picrylhydrazyl (DPPH).32 In vitro studies utilizing rat’s 
primary hepatocytes demonstrated that berberine at the 
concentrations of 0.01 - 1.0 mM significantly decreased 
the leakage of lactate dehydrogenase (LDH) and alanine 
aminotransferase (ALT), and the formation of 
malondialdehyde (MDA) after treatment with t-BHP (1.5 
mM) for 30 minutes. In addition, berberine attenuates the 
t-BHP-induced depletion of liver glutathione (GSH) and 
inhibits the t-BHP-induced genotoxicity in hepatocytes. In 
vitro studies showed that intra-peritoneal pre-treatment 
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with berberine at dose of 0.5 and 5 mg/kg for 5 days 
before a single dose of t-BHP (0.1 mmol/kg) significantly 
prevents the elevation of the liver transaminases and 
reduced oxidative stress in the liver. Therefore, berberine 
inhibits the hepatotoxicity induced by t-BHP through its 
antioxidative potential suggesting that it may play a 
chemo-preventive role by reducing oxidative stress in 
living systems. In addition, it is claimed that beberine 
could inhibit CYP2E1 mediated oxidation of p-nitrophenol 
in vitro.33 Zhao et al (2007) reported that oral 
administration of berberine (50 mg/kg) inhibited the 
hepatocyte proliferation and inducible nitrix oxide 
synthase (iNOS) expression, decreased CYP450 content, 
and inhibited activities of CYP2E1 and CYP1A2 in 
diethylnitrosamine (DEN)–plus-phenobarbital (PB)–
treated rat in vivo.34 Berberine (10, 50 and 100 µM) was 
also found to inhibit the activities of CYP2E1 and 
CYP1A2 in microsomal isolated from DEN-plus-PB-
treated rats in vitro suggesting that the anti-
hepatocarcinogenetic potential of berberine might be due 
to the inhibition of oxidative metabolic activities of 
CYP2E1 and CYP1A2 and the decrease of nitric oxide 
(NO) production in rats. 
 
Other activities 
Kong et al (2004) found that berberine upregulates 
low-density lipoprotein receptor (LDLR) expression in 
human hepatocytes through an extracellular signal-
regulated kinase (ERK)-dependent mechanism.35 These 
researchers found that berberine significantly lowered 
blood cholesterol, triglyceride and LDL cholesterol (LDL-
C) in patients with hyperlipidemia and elevated LDLR 
expression in the hepatitis B virus (HBV) full genome-
infected human hepatocytes. In addition, berberine 
reduced blood lipid, cholesterol, triglyceride and LDL-C in 
the hyperlipidemic hepatitis C and liver cirrhosis. The 
study suggested that berberine could be an ideal drug to 
control lipid metabolism alone or in combination for the 
patients with hyperlipidemic hepatitis or liver cirrhosis.36 
Moreover, it was shown that berberine induced c-Jun 
binding to LDLR promoter in berberine-induced LDLR 
transcription. Also, it was demonstrated that berberine 
increases transcriptional activity of LDLR promoter and 
this involves JNK pathway.37  
The suppressive effects of berberine on receptor 
activator of nuclear factor κB (NF-κB) ligand (RANKL)-
induced formation and survivals of osteoclast were 
studied. Berberine inhibited RANKL-mediated osteoclast 
formation and survival through the suppression of NF-κB 
and Akt pathways.38  
In addition, berberine was found to stimulate glucose 
uptake in a time- and dose-dependent manner. 
Investigation showed that it strongly promotes the 
phosphorylation of AMPK and p38 MAPK. These 
suggested that berberine circumvents insulin signaling 
pathways and stimulates glucose uptake through the 
AMP-AMPK-p38 MAPK pathway.39 Zhou et al (2007) 
showed that berberine stimulated glucose uptake in 3T3-
L1 adipocytes in a dose- and time-dependent way.40 
Berberine-stimulated glucose uptake was additive to that 
of insulin in 3T3-L1 adipocytes. In addition, berberine 
increased adenosine monophosphate-activated protein 
kinase and acetyl-coenzyme A carboxylase phosphor-
ylation. These findings indicated that berberine increases 
glucose uptake through a mechanism distinct from 
insulin, and stimulated adenosine monophosphate-
activated protein kinase seems to be involved in the 
metabolic effect of berberine.  
 
Conclusion 
Berberine has been found in the roots, rhizomes, and 
bark of a number of plants and it has been demonstrated 
to have significant physiological effects. These include 
antimicrobial activities against a variety of organisms, 
intestinal parasite infections, and ocular trachoma 
infections. It has been reported to act against 
hypertension, inflammation, HIV, tumors, and have 
antiprotozoal, chloretic, cholagogue, cardiotonic, 
anticholinergic, antiarrhythmic effects, and antiplatelet 
aggregation. In addition, berberine has been shown to 
affect blood lipid, cholesterol, triglyceride, LDL-C and 
glucose uptake.  
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